

Dirk G. Brockstedt
















Dirk Brockstedt, PhD, SVP, Research & Development, Aduro Biotech













Dirk G. Brockstedt is Senior Vice President of Research and Development, and has more than 18 years of experience in the fields of immunology and oncology originating with his PhD from Stanford University. He was the third employee in the original Immunotherapy group at Cerus Corporation and later brought the technology to Aduro Biotech, Inc. where he was instrumental in the development of both the live-attenuated and killed Listeria strains, and he led the development of the lead product, CRS-207. Prior to Cerus Corporation, Dr. Brockstedt spent 4 years at Aventis in the Immunotherapy and Anti-Angiogenesis group developing novel therapies against cancer. Dr. Brockstedt is the author of 35 peer-reviewed scientific articles and is a named inventor on 5 issued patents and several patent applications. Dr. Brockstedt received his B.A. in Microbiology and Immunology from the University of Kiel, Germany; he earned his Ph.D. jointly at the University of Kiel and Stanford University, and he was a post-doctoral fellow at Stanford University.


                  
















Dirk Brockstedt, Aduro Biotech Inc: Profile & Biography - Bloomberg


































































  






















Feedback





Dirk Brockstedt

Exec VP:Research & Development,
Aduro Biotech Inc






Career History




Exec VP:Research & Development
Aduro Biotech, 3/2016-PRESENT


Senior VP:Research & Dev
Aduro Biotech, 9/2011-3/2016



Aduro Biotech, 4/2009-UNKNOWN



Aventis, FORMER


Show More









Website:
www.aduro.com






Corporate Information
Address:

740 Heinz Avenue
Berkeley, CA 94710-2224
United States


Phone:
1-510-848-4400


Fax:
-


Web url:
www.aduro.com











From The Web












Personal Information



Education



Stanford University
PhD








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data

































Dirk G. Brockstedt Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 27, 2017 3:22 AM ET
Biotechnology

Company Overview of Aduro BioTech, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Dirk G. Brockstedt Ph.D.Executive Vice President of Research and Development, Aduro BioTech, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 1 different industries.48--
Background

		Dr. Dirk G. Brockstedt, Ph.D., has been an Executive Vice President of Research and Development at Aduro BioTech, Inc. since March 2016. Dr. Brockstedt served as Senior Vice President of Research and Development at Aduro BioTech, Inc. since September 2011. Dr. Brockstedt served as Vice President of Research and Development at Aduro BioTech, Inc. Dr. Brockstedt has more than 15 years of experience in the fields of immunology and oncology. He was the third employee in ... the original Vaccine group at Cerus Corporation and later brought the technology to Aduro. He was instrumental in the development of both the live-attenuated and killed Listeria strains and he led the development of the lead product, CRS-207. Prior to Cerus Corporation, Dr. Brockstedt spent 4 years at Aventis in the Immunotherapy and Anti-Angiogenesis group developing novel therapies against cancer. He is the author of more than 20 peer-reviewed scientific articles and is a named inventor on 5 issued patents and several patent applications. He holds his PhD from Stanford University.Read Full Background




Corporate Headquarters
740 Heinz AvenueBerkeley, California 94710United StatesPhone: 510-848-4400Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
PhD Stanford UniversityMS Christian Albrechts Universität Kiel
Other Affiliations
Stanford UniversityChristian Albrechts Universität Kiel


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationJ. Joseph Kim Ph.D.CEO, President & DirectorInovio Pharmaceuticals, Inc.$1.0MSteven W. King CEO, President, Director, CEO of Avid Bioservices Inc and President of Avid Bioservices Inc Peregrine Pharmaceuticals, Inc.$520.0KMark R. Baker J.D.Chief Executive Officer and DirectorProgenics Pharmaceuticals, Inc.$646.8KEddie  Gray Chief Executive Officer and DirectorDynavax Technologies Corporation$600.0KLaurence James Neil Cooper Ph.D., M.D.Chief Executive OfficerZIOPHARM Oncology, Inc.$1.2MCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Aduro BioTech, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


































For full functionality of ResearchGate it is necessary to enable JavaScript.
                    Here are the 
                        instructions how to enable JavaScript in your web browser.






Please, wait while we are validating your browser




    Dirk Brockstedt | ADURO BIOTECH, INC. | ZoomInfo.com    Dirk Brockstedt | ADURO BIOTECH, INC. | ZoomInfo.com 

Leadership | Aduro Biotech



















Pioneering Immunotherapy.
Transforming Lives.


Leadership








Stephen T. Isaacs

Chairman, President and CEO



Thomas W. Dubensky, Jr., Ph.D.

Chief Scientific Officer





Natalie R. Sacks, M.D.

Chief Medical Officer



Gregory W. Schafer

Chief Operating Officer





Hans van Eenennaam, Ph.D.

Chief Operational Officer, Aduro Biotech Europe



Andrea van Elsas, PH.D.

Chief Scientific Officer, Aduro Biotech Europe



 


Dirk G. Brockstedt, Ph.D.

Executive Vice President, Research & Development



Jennifer Lew

Senior Vice President, Finance





Quoc Le-Nguyen

Senior Vice President, Chemistry, Manufacturing and Control



Blaine Templeman

Executive Vice President, General Counsel and Secretary





Sylvia Wheeler

Senior Vice President, Corporate Affairs and Investor Relations




 


Michele DeVries

Vice President, Regulatory Affairs



Celeste Ferber

Vice President, Associate General Counsel





Nancy Kaplan

Vice President, Human Resources and Facility Operations



Anne Moon, Ph.D.

Vice President, Project Management





Aimee Murphy

Vice President, Clinical Development and Operations



Justin Skoble, Ph.D.

Vice President, Technical Operations





Liana Wu

Vice President, Commercial





Stephen T. Isaacs

Chairman, President and CEO


Stephen T. Isaacs has served as our Chairman, President and Chief Executive Officer since 2008. Prior to Aduro, in 1991, Mr. Isaacs founded Cerus Corporation, a biomedical products company that commercialized the Intercept Blood Systems. He served as President and Chief Executive Officer of Cerus from 1991 to 2004. Prior to Cerus, Mr. Isaacs founded and served as Chief Executive Officer and President of HRI Associates and HRI Research, both biotechnology companies focused on research and development. He held a non-teaching faculty position in the Department of Chemistry at the University of California, Berkeley, from 1978 to 1986. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. Mr. Isaacs holds a B.A. degree in Biochemistry from University of California, Berkeley, and had graduate training in organic chemistry in the Ph.D. program in the Department of Chemistry at Berkeley. 


Thomas W. Dubensky Jr., Ph.D.

Chief Scientific Officer


Thomas W. Dubensky Jr., Ph.D., has served as our Chief Scientific Officer since September 2011. From 2009 to 2011, Dr. Dubensky served as Chief Scientific Officer of Immune Design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. Prior to this, in 2007 he co-founded and served as Chief Scientific Officer of Anza Therapeutics, a biotechnology company that was spun out from Cerus Corporation where he had served as Vice President of Research for the five years prior.  During this time, Dr. Dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes, which serves as the technology basis for Aduro’s LADD platform. Earlier in his career, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA at a number of biotechnology companies, including Viagene, Chiron Corporation and Onyx Pharmaceuticals. Dr. Dubensky has co-authored more than 70 scientific papers and is an inventor on 35 issued U.S. patents with multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley, and his Ph.D. at the University of Colorado Health Sciences Center.  He conducted his post-doctoral fellowship at Harvard Medical School in the Department of Pathology.


Natalie R. Sacks, M.D.

Chief Medical Officer

Natalie Sacks, M.D., has served as our Chief Medical Officer since September 2016. Prior to joining Aduro, Dr. Sacks served as an advisor on development strategy for multiple firms. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen) where she played a key role in the development and approval of Kyprolis®, an FDA-approved therapy for the treatment of relapsed or refractory multiple myeloma, and in business development strategy. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, with responsibilities ranging from IND filings to late-stage development, including late-stage development of Cometriq™, an FDA-approved therapy for the treatment of medullary thyroid cancer. Earlier in her career, Dr. Sacks served as Vice President of Clinical Development at Cell Genesys, a company focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cells. Prior to her tenure in biotechnology, she served in a variety of research and analytical roles at academic institutions and companies, including Massachusetts General Hospital, Medical College of Pennsylvania, and ICI-Stuart Pharmaceuticals. In addition to her industry experience, Dr. Sacks holds an active faculty appointment at the University of California, San Francisco, where she is an assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College.


Gregory W. Schafer

Chief Operating Officer


Gregory W. Schafer has served as our Chief Operating Officer since July 2013. Prior to joining Aduro, he served as Chief Financial Officer of Jennerex Biotherapeutics (acquired by Sillajen), a privately held biotechnology company, from June 2010 to July 2013, where he was responsible for finance, accounting, planning, investor relations and treasury functions. From April 2006 to January 2009, he served as Chief Financial Officer of Onyx Pharmaceuticals (acquired by Amgen) where he was responsible for finance, accounting, risk management and strategic and operational planning. Earlier in his career, Mr. Schafer served as Chief Financial Officer and Vice President of Finance for IntraBiotics Pharmaceuticals and Cerus Corporation. Prior to entering the field of biotechology, he worked as a management consultant for Deloitte & Touche LLP. He received his M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles, and a B.S.E. in mechanical engineering from the University of Pennsylvania.


Hans van Eenennaam, Ph.D.

Chief Operational Officer, Aduro Biotech Europe


Hans van Eenennaam, Ph.D., became Chief Operational Officer of Aduro Biotech Europe in November 2015. Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operational officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field of immune oncology.  Earlier in his career, he held numerous positions of increasing responsibility at Organon in Oss, Netherlands, and the Organon Research Center in Cambridge, Massachusetts, which was acquired by Schering-Plough Corporation in 2007 and later by Merck & Co. He led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology.  While at Organon, Dr. van Eenennaam, in cooperation with a team of scientists, discovered pembrolizumab (Keytruda®), a humanized therapeutic antibody acquired by Merck and approved in 2014 by the U.S. Food and Drug Administration for the treatment of melanoma and subsequently for additional indications including, non-small cell lung cancer and head and neck cancer.  In 2016, he and colleagues were honored by the Intellectual Property Owner’s Association with the 43rd Annual Inventor of the Year Award. He is named as inventor on seven pending and granted patent families, including the patents claiming Keytruda, and author on over 25 publications.  Dr. van Eenennaam received his doctorate in autoimmune biochemistry (cum laude) from Radboud University in Nijmegen, Netherlands.


Dr. Andrea van Elsas, Ph.D.

Chief Scientific Officer, Aduro Biotech Europe


Andrea van Elsas became Chief Scientific Officer of Aduro Biotech Europe in November 2015.  Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology.  From 1999 to 2011, he held numerous positions at Organon in Oss, Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.  


Dirk G. Brockstedt, Ph.D.

Executive Vice President, Research & Development


Dirk G. Brockstedt, Ph.D., joined Aduro in April 2009 and has served as our Senior Vice President of Research and Development since September 2011. Prior to joining Aduro, Dr. Brockstedt held various positions of increasing responsibility in the immunotherapy group at Cerus Corporation, culminating as Director of Immunology.  Earlier in his career, Dr. Brockstedt worked as a scientist at Aventis in the Immunotherapy and Anti-Angiogenesis group from 1999 until 2002, focused on developing novel anti-cancer therapies. He has co-authored 40 scientific papers and is a named inventor on five issued patents and several pending applications. Dr. Brockstedt holds a Diploma/Masters of Science in Microbiology from the University of Kiel and earned his Ph.D. from the University of Kiel and Stanford University, the latter at which he served as a post-doctoral fellow at the Stanford School of Medicine in the department of Pathology.


Jennifer Lew

Senior Vice President, Finance


Jennifer Lew joined Aduro in October 2013 and has served as our Senior Vice President of Finance since January 2015. Prior to joining Aduro, from 2004 to 2013, Ms. Lew held various positions of increasing responsibility at Dynavax Technologies, culminating as Vice President of Finance and Principal Accounting Officer responsible for all accounting and finance operations. Earlier in her career Ms. Lew served as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Ms. Lew earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).


Quoc Le-Nguyen

Senior Vice President, Chemistry, Manufacturing and Control


Quoc Le-Nguyen joined Aduro in September 2015 and has served as our Senior Vice President of Chemistry, Manufacturing and Control (CMC) since September 2016. He brings over 25 years of experience in biopharmaceutical operations, having held positions of increasing responsibility at both large pharmaceutical and start-up companies. Prior to joining Aduro, Mr. Le-Nguyen spent seven years at Bayer Healthcare as the Vice President of Technical Operations. Before Bayer, he served at Chiron Corporation (and Novartis AG) as Director of Manufacturing Operations. Earlier in his career, he served as Senior Manager of Manufacturing Operations at BioMarin Pharmaceutical, where he played an integral role in bringing the company’s lead drug candidate from Phase 3 to commercial launch. Mr. Le-Nguyen holds a B.S. from University of California, Davis in Biochemistry.


Blaine Templeman

Executive Vice President, General Counsel and Secretary


Blaine Templeman joined Aduro as Executive Vice President, General Counsel and Secretary in September 2015. He brings over 20 years of experience counseling biotechnology companies in the development and commercialization of their products. Prior to joining Aduro, Mr. Templeman was a corporate and intellectual property partner at Arnold & Porter LLP, where he counseled U.S. and international clients on the protection, development and commercialization of their products, intellectual property portfolios, contract manufacturing, clinical trials, research and outsourcing. His transactional experience includes a variety of collaborations, licensing transactions, mergers and acquisitions, asset sales, manufacturing and distribution arrangements and co-promotion transactions. Before Arnold & Porter LLP, he was a partner at Heller Ehrman. Mr. Templeman holds a J.D. from New York University and a B.S. from Oral Roberts University.


Sylvia Wheeler

Senior Vice President, Corporate Affairs and Investor Relations


Sylvia Wheeler joined Aduro as Senior Vice President, Corporate Affairs and Investor Relations in January 2015. She brings over 20 years of experience in the biopharmaceutical industry, having served in a number of executive management roles encompassing investor and media relations, as well as corporate and product communications. Prior to joining Aduro, Ms. Wheeler served as Vice President of Investor Relations and Corporate Affairs at Relypsa after having served this same role for Hyperion Therapeutics. Earlier in her career, she was Vice President, Corporate Communications at Affymax where, over a six-year-period, she supported the company’s transition from a research and development company to a commercial organization with its first marketed product. Ms. Wheeler held similar communications roles at Depomed, Cerus Corporation and Coulter Pharmaceutical. Ms. Wheeler holds an M.B.A. from University of San Francisco and a B.A. in Biology from San Francisco State University.


Michele DeVries

Vice President, Regulatory Affairs

Michele DeVries joined Aduro in 2013 and currently serves as Vice President of Regulatory Affairs.  She is responsible for all aspects of regulatory strategy, implementation and oversight of Aduro’s proprietary, partnered and licensed programs, both in the U.S. and internationally. Prior to Aduro, Ms. DeVries served as Director of Regulatory Affairs for Intarcia Therapeutics.  In this role she managed key regulatory aspects of Intarcia’s drug delivery system, served as the primary contact for regulatory authorities, and was responsible for all aspects of routine and specialized regulatory submissions, including preparation for launch of four global Phase 3 studies. Before Intarcia, she held escalating regulatory affairs positions at VaxGen, InterMune and Tularik.  She received her B.S. in Chemical Engineering from the University of Minnesota.


Celeste Ferber

Vice President, Associate General Counsel

Celeste Ferber joined Aduro in 2016 and currently serves as Vice President, Associate General Counsel. Prior to Aduro, she was with Shearman & Sterling LLP, where she served as counsel in the capital markets group.  Ms. Ferber has over 15 years of experience advising public and private companies on corporate and finance matters, including securities offerings, mergers, acquisitions and strategic transactions, corporate governance and securities law compliance. Before Shearman & Sterling, Ms. Ferber was counsel at Morrison & Foerster LLP working in their Palo Alto, Hong Kong and San Diego offices. Ms. Ferber received her J.D. from the University of California, Hastings College of Law and her B.A. in Economics from Bucknell University. She is the author of numerous publications regarding legal matters.


Nancy Kaplan

Vice President, Human Resources and Facility Operations


Nancy Kaplan joined Aduro in 2008 and currently serves  as Aduro’s Vice President of Human Resources and Facility Operations. Prior to Aduro, Ms. Kaplan worked with a wide variety of small biotech companies, applying her broad generalist skill set to establish and bolster finance, human resources, facility management, grant administration and investor relations functions. In addition, she was Marketing Communications Manager at Applied Biosystems and supervised biotech accounts at Lena Chow Advertising. Earlier in her career, Ms. Kaplan was part of the founding group at Invitron Corp, a mammalian cell contract manufacturer. Ms. Kaplan holds a B.S. in Agronomy from Oregon State University.


Anne Moon, Ph.D.

Vice President, Project Management


Anne Moon, Ph.D., joined Aduro in 2014 and currently serves as Vice President of Project Management. Prior to Aduro, Dr. Moon was a founding team member of Jennerex Biotherapeutics (acquired by SillaJen), where she served as Vice President of Product Development. Earlier in her career, Dr. Moon was part of the start-up team at Cytokinetics, establishing the cell-based screening program and served as Project Manager of the oncolytic virus program at Onyx Pharmaceuticals (acquired by Amgen) after completing postdoctoral work within the small molecule therapeutics program targeting small GTPases. She received her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and her B.A. in Biology from Harvard University.


Aimee Murphy

Vice President, Clinical Development and Operations


Ms. Murphy joined Aduro in 2009 and currently serves as Vice President of Clinical Development and Operations.  Prior to Aduro, Ms. Murphy advanced the development of the LADD (live, attenuated double-deleted) immunotherapy platform at both Cerus Corporation and Anza Therapeutics, where she managed the first Phase 1 studies that led to Aduro's existing LADD clinical programs. Prior to focusing on LADD, she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at VaxGen, Coulter Pharmaceuticals, and Shaman Pharmaceuticals. Additionally, Ms. Murphy brings experience in quality assurance from Bayer Pharmaceuticals. She holds a B.S. in Biology from Pepperdine University.


Justin Skoble, Ph.D.

Vice President, Technical Operations


Justin Skoble, Ph.D., joined Aduro in 2009 and currently serves as Aduro’s Vice President of Technical Operations. Prior to Aduro, Dr. Skoble held positions with increasing responsibilities in the molecular biology and process development departments at Anza Therapeutics and Cerus Corporation. He earned his B.A. in Biology from Vassar College and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, in the laboratory of Dr. Daniel Portnoy. Additionally, Dr. Skoble performed postdoctoral work at the University of California, San Francisco (UCSF), in the laboratory of Dr. Jeff Cox, Professor of Microbiology and Immunology at UCSF.


Liana Wu

Vice President, Commercial


Liana Wu joined Aduro in April 2015 as Vice President, Commercial, bringing with her over 17 years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches. Prior to Aduro, Ms. Wu spent nine years at Onyx Pharmaceuticals (acquired by Amgen) where she was most recently Vice President, Oncology Franchise. While at Onyx, she was instrumental in overseeing the collaboration with Bayer for Nexavar and Stivarga in the United States.  Earlier in her career, Ms. Wu held several sales and marketing positions at Genentech, with responsibilities associated with the company’s key oncology brands, including Rituxan, Herceptin, and Tarceva. Ms. Wu holds a Master’s in Public Health from The Johns Hopkins University and a B.S. in Economics from the Wharton School at the University of Pennsylvania.










Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs








Home


About Us



Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs





Pipeline



Clinical Trials


Access to Our Investigational Agents





Technology



Immunotherapy


LADD


STING Pathway


B-select Antibodies


Scientific Publications


Intellectual Property





Partnerships


Media



Press Releases


Corporate Video





Investors



Press Releases


Events & Presentations


Corporate Governance



Leadership


Board of Directors


Committee Composition





Financials & Filings



Financial Reports


Quarterly Results





Analyst Coverage


Stock Information



Stock Chart





FAQs







Careers


Contact











Home


About Us



Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs





Pipeline



Clinical Trials


Access to Our Investigational Agents





Technology



Immunotherapy


LADD


STING Pathway


B-select Antibodies


Scientific Publications


Intellectual Property





Partnerships


Media



Press Releases


Corporate Video





Investors



Press Releases


Events & Presentations


Corporate Governance



Leadership


Board of Directors


Committee Composition





Financials & Filings



Financial Reports


Quarterly Results





Analyst Coverage


Stock Information



Stock Chart





FAQs





Careers


Contact


Privacy Policy


Terms and Conditions of Use








© 2017 Aduro BiotechAll rights reserved


Privacy Policy


Terms and Conditions of Use


Website Design: Hane Chow, Inc.

TwitterLinkedIn




















